|
|
Blood, 15 August 2006, Vol. 108, No. 4, pp. 1334-1338.
Prepublished online as a Blood First Edition Paper on May 2, 2006; DOI 10.1182/blood-2005-12-011213.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
Amy J. Johnson,
David M. Lucas,
Natarajan Muthusamy,
Lisa L. Smith,
Ryan B. Edwards,
Michael D. De Lay,
Carlo M. Croce,
Michael R. Grever, and
John C. Byrd
From the Division of Hematology and Oncology, Departments of Internal Medicine and Molecular Virology, Immunology, and Medical Genetics, College of Medicine, and Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus.
Drug development in human chronic lymphocytic leukemia (CLL) has been limited by lack of a suitable animal model to adequately assess pharmacologic properties relevant to clinical application. A recently described TCL-1 transgenic mouse develops a chronic B-cell CD5+ leukemia that might be useful for such studies. Following confirmation of the natural history of this leukemia in the transgenic mice, we demonstrated that the transformed murine lymphocytes express relevant therapeutic targets (Bcl-2, Mcl-1, AKT, PDK1, and DNMT1), wild-type p53 status, and in vitro sensitivity to therapeutic agents relevant to the treatment of human CLL. We then demonstrated the in vivo clinical activity of low-dose fludarabine in transgenic TCL-1 mice with active leukemia. These studies demonstrated both early reduction in blood-lymphocyte count and spleen size and prolongation of survival (P = .046) compared with control mice. Similar to human CLL, an emergence of resistance was noted with fludarabine treatment in vivo. Overall, these studies suggest that the TCL-1 transgenic leukemia mouse model has similar clinical and therapeutic response properties to human CLL and may therefore serve as a useful in vivo tool to screen new drugs for subsequent development in CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Of mice and men...
- John G. Gribben
Blood 2006 108: 1115-1116.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. T. S. Bertilaccio, C. Scielzo, G. Simonetti, M. Ponzoni, B. Apollonio, C. Fazi, L. Scarfo, M. Rocchi, M. Muzio, F. Caligaris-Cappio, et al.
A novel Rag2-/-{gamma}c-/--xenograft model of human CLL
Blood,
February 25, 2010;
115(8):
1605 - 1609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-S. Chen, A. Raval, A. J. Johnson, E. Hertlein, T.-H. Liu, V. X. Jin, M. H. Sherman, S.-J. Liu, D. W. Dawson, K. E. Williams, et al.
Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
PNAS,
August 11, 2009;
106(32):
13433 - 13438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Lucas, R. B. Edwards, G. Lozanski, D. A. West, J. D. Shin, M. A. Vargo, M. E. Davis, D. M. Rozewski, A. J. Johnson, B.-N. Su, et al.
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
Blood,
May 7, 2009;
113(19):
4656 - 4666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Gorgun, A. G. Ramsay, T. A. W. Holderried, D. Zahrieh, R. Le Dieu, F. Liu, J. Quackenbush, C. M. Croce, and J. G. Gribben
E{micro}-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
PNAS,
April 14, 2009;
106(15):
6250 - 6255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q.-L. Wu, C. Zierold, and E. A. Ranheim
Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia
Blood,
March 26, 2009;
113(13):
3031 - 3039.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. A. Andritsos, A. J. Johnson, G. Lozanski, W. Blum, C. Kefauver, F. Awan, L. L. Smith, R. Lapalombella, S. E. May, C. A. Raymond, et al.
Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2008;
26(15):
2519 - 2525.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. De Lay, A. J. Johnson, D. M. Lucas, D. T. Durr, E. M. Sass, V. M. Goettl, A. Lehman, D. Jarjoura, M. R. Grever, and J. C. Byrd
Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL).
Blood (ASH Annual Meeting Abstracts),
November 16, 2007;
110(11):
3095 - 3095.
[Abstract]
|
|
|
|
|
